NuVasive - NUVA Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings or view top-rated stocks.

12 Wall Street research analysts have issued 1-year price targets for NuVasive's shares. Their NUVA share price forecasts range from $53.00 to $83.00. On average, they expect the company's stock price to reach $60.27 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.

NuVasive's stock was trading at $52.48 on January 1st, 2022. Since then, NUVA stock has decreased by 17.5% and is now trading at $43.27.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our NUVA earnings forecast.

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Wednesday, August, 3rd. The medical device company reported $0.47 EPS for the quarter, missing analysts' consensus estimates of $0.55 by $0.08. The medical device company had revenue of $310.45 million for the quarter, compared to analyst estimates of $305.83 million. NuVasive had a positive trailing twelve-month return on equity of 11.12% and a negative net margin of 3.41%.

NuVasive announced that its board has authorized a stock repurchase plan on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.5% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's management believes its stock is undervalued.

NuVasive issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of $2.15-$2.45 for the period, compared to the consensus EPS estimate of $2.31. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.22 billion.

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $43.27.

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.25 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

The company employs 2,900 workers across the globe.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.